TAKEDA WINS PATENT INFRINGEMENT LITIGATION AGAINST ANDA
Takeda Pharmaceutical Company Limited (Takeda) and its wholly owned subsidiary,
Takeda Pharmaceuticals North America Inc. (TPNA) announced on Wednesday that Takeda's
intellectual property rights (IPRs) have been successfully asserted against generic
manufacturers seeking to challenge Takeda's patent rights to ACTOS (pioglitazone
HCl). According to a press release by the company, a federal judge of the US District
Court for the Southern District of New York ruled on February 21, 2006, that a
patent covering the active ingredient of ACTOS is valid and enforceable.